RADIOTHERAPY
CURES CANCER TODAY
Help us close the gap in access to treatment
5 December 2017
17:00 – 19:00
European Parliament, Brussels,
Room ASP 5G1
Organised by the European Society for RadioTherapy and Oncology (ESTRO)
and Ms Lieve Wierinck MEP
EVENT REPORT
The event is supported by the MEPs Against Cancer Group
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 2
“Radiotherapy cures cancer today, help us close
the gap in access to treatment” was the driving theme
of the event organised by Ms Lieve Wierinck, Belgian
Member of the European Parliament (Member of the
Alliance of Liberals and Democrats for Europe - ALDE),
and the European Society for Radiotherapy and Oncology
(ESTRO) and supported by the MEPs Against Cancer
group, on the 5th of December 2017 at the European
Parliament.
Over 65 policy-makers, experts in cancer care, patients,
health advocates, industry representatives, delegates
from national radiotherapy societies and citizens gathered
to discuss access to radiation oncology care for all
patients in need in Europe, during the conference.
In her capacity as host of the event, Ms Lieve Wierinck
welcomed the participants and thanked ESTRO for the
partnership. She outlined that cancer is still the second
most common cause of death in Europe. Despite the
key role of radiotherapy in cancer treatment, there is a
large number of patients who do not get the needed
radiotherapy. Substantial disparities exist in the availability
of such treatments between countries, most European
countries do not have the required resources to provide
radiotherapy to their population. She welcomed and
expressed support to the ESTRO-led HERO (Health
Economics in Radiation Oncology) project, which maps
the provision and accessibility of radiotherapy in Europe,
along with the need for radiotherapy and now engaging
in the assessments of the national cost of radiotherapy
delivery.
The first keynote presentation was provided by Prof
Cai Grau, co-chair of the HERO group and Radiation
Oncologist at the Aarhus University Hospital. His
presentation focused on access to radiation oncology in
Europe, recalling ESTRO’s vision that “every cancer patient
in Europe will have access to state of the art radiation
therapy” by 2020. He introduced the HERO framework,
focusing on the first work package, namely the availability of
radiotherapy in Europe. His talk mentioned the substantial
disparities between European countries regarding
access to radiotherapy resources, depending also on the
economic status of the countries. He pointed out that high-
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 3
income countries especially in the North-Western parts
of Europe are better served with radiotherapy resources
than other countries, which face important shortages
of equipment able to deliver high precision conformal
treatment. In addition, significant disparities in available
staff were detected, calling for strong, harmonised training
programmes. To tackle the disparities and plan efficiently
the resources, we need accurate prediction models and
long-term planning. Therefore, and most importantly, “it
is time to start tackling the inequalities and shortages”, he
concluded.
Prof. Josep M. Borras, Epidemiologist at the University of
Barcelona, addressed the topic of unmet needs of cancer
patients for radiation oncology and the importance of
cancer planning. One in two cancer patients in Europe
should receive radiation oncology during the course of
their fight against cancer but a quarter do not receive the
radiation oncology they need. He reviewed how the gap
between the actual and the optimal use of radiotherapy
and the importance of cancer planning can be assessed, in
order to improve the situation. To this end not only data is
needed, but also the translation of data into an appropriate
cancer plan. Furthermore, the magnitude of the gap
needs to be evaluated and reasonable targets have to be
set, in order to define policies aiming at closing the gap.
The data he presented give evidence that radiotherapy
is currently underutilized in most European countries.
When addressing the future needs, projections show that
many of the European countries will face severe risks of
radiotherapy shortages in the next decades - in some EU
countries the need for radiotherapy will grow above 20%.
Overall, he concluded that data are important and that
data collection should be stimulated in Europe, in order
to assess the need at national level. A combined effort
of policymakers, scientific societies and patients and a
long-term planning for radiotherapy resources and staff
are required, though the situation has improved over the
past years in the form of partnerships between Member
States, the European Commission, patient organizations
and scientific societies. Finally, he stated that National
Cancer Control Programmes offer the right framework to
overcome challenges posed by an increasing number of
patients, the availability of new technologies and the need
of multidisciplinary teams.
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 4
Prof Yolande Lievens, ESTRO President, co-chair of
the HERO group and Radiation Oncologist at Ghent
University Hospital, discussed the value of radiation
oncology. While cost-effectiveness analysis focused
initially very much on costing, in the last years the focus
has shifted to value, intended as value for the patients.
Focusing on radiotherapy, it has been observed that
side effects significantly decreased and state-of-the-art
radiotherapy does improve quality of life and also survival.
Building on evidence from the Global Task Force on
Radiotherapy for Cancer Control (2015) she concluded
that radiotherapy does not only save lives (globally, it is
estimated that access to radiotherapy can save 1 million
lives) but pays off in terms of Human Capital Benefits and
even more in terms of Full Income Benefits, especially if we
move towards more advanced techniques. When looking
at the expenditures for radiotherapy however we find a
disbalance in comparison to other cancer treatments.
Only 5-10% of the healthcare budgets in Europe for cancer
care is spent on radiotherapy. While one out of two cancer
patients requires radiotherapy, this spending rate can be
considered low. A particular concern that Prof Lievens
emphasized is the need to close gaps regarding access to
care. To support timely access, it is important to generate
evidence.
Prof Lievens announced the launch of a new tool in the
HERO project, which aims at calculating the actual cost and
resources usage of External Beam Photon Radiotherapy
(EBRT) at national level in Europe. Her presentation
concluded with a quote of the founder of Value Based
Healthcare, Michael Porter, stating that “achieving high
value for patients must become the overarching goal of
health care delivery”.
Andrzej Rys, Director for “Health systems, medical
products and innovation” at the European Commission
Directorate General for Health and trained radiologist,
presented the role of the European Commission in
strengthening healthcare systems in the context of cancer
care. He started his speech by discussing the human
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 5
resources challenge, which was mentioned in the previous
presentations and is of paramount importance. “It is easier
to buy machines then get people who are able to work with
the machines”, he noted. Referring to the work and role of
the European Commission, Dr Rys pointed at the recently
published 28 country health profiles and companion
report, part of the “State of Health in the EU” cycle, a two-
year initiative of the Commission providing stakeholders
with comparative data and insights into the health status
of Europeans and health systems of EU countries. Main
findings of the report include the importance of integrated
care and health workforce planning. He also highlighted
that one of the current Commission’s flagship initiatives
is to prepare a new EU initiative on HTA, which is close
to finalisation. In this project the Commission will focus
on the clinical assessment, without going into pricing and
reimbursement issues, which is left to the Member States.
The aim is to improve the current EUnetHTA (European
Network on HTA), to turn it into an improved and more
sustainable network, with the overall aim to establish a
permanent cooperation in the EU on HTA. The topic of
digitalization and the collection of real world data was
raised, with the observation that the preparatory work
to define methodologies of assessment, standardization
and ways to share data is a prerequisite before any further
implementation. Dr Rys emphasized the continuous
investments of the Commission and especially mentioned
two areas: The European Reference Networks (ERNs),
and the Innovative Medicines Initiative, in which he called
for participation from the medical device industry.
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 6
Further to the discussions, a panel debate was convened
on the topic of “How to foster positive policy
environments at EU and national levels to ensure
equal access to radiation oncology care for all patients
in need, as part of the multimodality treatment of
cancer?”, which was moderated by well-known EU-
accredited Brussels-based journalist Peter O’Donnell.
During the exchange of views, Ms Wierinck underlined
the power of the patients and the need to work in a multi-
stakeholder way, to guarantee every person in Europe the
same quality of health.
Ms Nicole Denjoy, Secretary General of the European
Coordination Committee of the Radiological,
Electromedical and Healthcare IT Industry (COCIR),
pointed at the need for a digital transformation of health
systems. Innovation has to be in accordance with the
needs of the patients. She also outlined the importance of
patient focused approaches, and the need to place further
emphasis on outcomes. The industry can and should be
part of the solution to overcome challenges, it is crucial to
work in partnerships and ensure that healthcare systems
allow patient access to innovative technologies.
Dr Tit Albreht, Head of the Health Care Centre at the
National Institute of Public Health of Slovenia, discussed
the role that EU-funded Joint Actions can play in addressing
some of the issues that are currently being faced. He
referred to three instruments that help to manage care
from different perspectives: Guidelines, Patient Pathways
and Cancer Control Programmes. According to Dr
Albreht, coordinator of the recently ended Joint Action on
Cancer Control (CanCon), Joint Actions do not have the
time nor the capacity to help developing guidelines, patient
pathways are on the other hand extremely important to
identify the needs and requirements of patients to finally
plan resources. Tit Albreht also referred to the role of HTA,
which he noted is too much focused on medicines. Other
technologies are more challenging and in that sense the
HERO project can be important, he noted.
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 7
Dr Jean-Francois Daisne, President of the Belgian Society
for Radiation Oncology (ABRO-BVRO), was invited by
Peter O’Donnell to discuss the necessities and potentials
of radiotherapy in Belgium. Dr Daisne mentioned
that Belgium has the potential of being a best practice
example in terms of availability of up-to-date services for
the patients, however some challenges remain, such as
small but numerous departments. Radiotherapy should
be more concentrated but at the same time also more
available. Collaborating in ESTRO’s HERO initiative gives
the opportunity to evaluate the Belgian model, its cost-
effectiveness and be able to provide information to policy-
makers.
Dr Edward Naessens, Chair of the ESTRO Patient
Advisory Group, emphasized the necessity of both a
bottom-up and a top-down approach in the pursuit
of optimal provision. The top-down approach should
however be predominantly used, so that basic provisions
are delivered to all European citizens, regardless of their
nationality or socioeconomic background, and the model
of best-practice is followed by all Member States. Patients
want European standards of care, he noted.
Prof Philip Poortmans, ESTRO past President and
ECCO President-elect, outlined ESTRO’s efforts to bring
radiation therapy to higher standards. A point that needs
to be improved is communication he noted, especially
between scientific societies and the European Institutions,
to ensure multidisciplinary care.
Participants were also invited to interact with the panel. A
representative of the European Cancer Care Organization
(ECCO) asked the European Commission to develop
further on the benefits of the forthcoming EU HTA
legislation for non-pharmaceuticals. Andrzej Rys, referred
to the investment from DG RTD in the Seventh Framework
Programme for Research and Innovation, to understand
which methodology can be used to assess devices. He
explained that this is a question of standardization of the
processes of collection and assessment of clinical data.
The commenced journey needs to be continued and more
research is needed.
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 8
Dr Tit Albreht stated that the EUnetHTA is the right place to further
develop and include different technologies. After highlighting the
need for dedicated methodologies for HTA for non-pharmaceuticals,
Ms Nicole Denjoy noted that the entire care pathway needs to be
assessed, especially when taking into account multidisciplinarity.
Ms Mary Coffey from the HERO Group, outlined the importance of
health care professionals’ education to deliver high quality care all over
Europe.
A representative of the European Society of Paediatric Oncology
(SIOP-Europe) underlined the importance of the EU Joint Action
on Rare Cancers funded by the EU Third Health Programme (2014-
2020). One of the tasks of the project SIOPE is involved in focuses on
the availability of radiotherapy equipment for children with cancer. She
pointed at the opportunity to collaborate with ESTRO and highlighted
that the work and findings of the HERO project are essential in this
regard.
To conclude the exchange, each panel member was given the floor to
provide a final reflection on how to foster a positive policy environment
at a EU and national level regarding access to, and quality of,
radiotherapy:
yDr Edward Naessens: Multidisciplinarity can be singled out
as the most important factor to ensure patients receive state-
of-the-art information and treatment.
yDr Jean Francois Daisne: More scientific and health economic
data needs to be collected. National societies are key structures
to communicate with policy makers to make better informed
decisions for the benefit of the patient.
yDr Tit Albreht: The crucial point is to meet patient needs and
there should be no imbalances between countries in access to
cancer care.
yProf Philip Poortmans: Patients need to be active partners,
every effort should always be with and around the patient
including in the context of multidisciplinarity or when engaging
in dialogue with policy-makers.
yMs Nicole Denjoy: Raising awareness of radiotherapy
is crucial. Building and strengthening partnerships is also
important to accelerate access to treatment, to maximize the
value of investment and to improve patient satisfaction. The
EU has a key role to play in helping with funding mechanisms
and achieving a better synchronization/harmonization between
hospitals.
Radiotherapy Cures cancer today - Help us close the gap in access to treatment 9
Concluding the event, Ms Wierinck raised the importance
of continuing dialogue between stakeholders, stressing that
she has been “on all sides”, in her past role as a pharmacist
(care provider), a patient and now as a policy-maker. She
encouraged all stakeholders to sustain the conversation with
policy makers and share knowledge and expertise to help
them make informed decisions. The role of the European
Parliament is to continue stimulating the debate on access
to radiotherapy, at both national and European levels, but
also boosting investment and education. The event ended
with a short video celebrating the valuable contribution of
Marie Skłodowska-Curie to the field of radiation oncology,
on the occasion of her 150th anniversary.
The EU has a key role to play in supporting Member
States improving the performance of national
healthcare systems and providing access to quality
healthcare services for patients. Ms Wierinck, ESTRO
and partners remain committed to pursue the discussions
to help make policy change happen towards the objective
of ensuring that more and more patients in need can access
radiotherapy to help them fight cancer.
Participants continued to exchange during a cocktail
reception that followed the event.
The event is supported by the MEPs Against Cancer Group
From: Jana Jaal <
[email protected]>
Sent: Wednesday, September 5, 2018 3:55 PM
To: Tervise- ja tööminister <
[email protected]>
Subject: Eesti Kliiniliste Onkoloogide Seltsi pöördumine kiiritusravi kättesaadavuse osas
Tere,
Käesolevaga pöördub Eesti Kliiniliste Onkoloogide Selts (EKOS) Sotsiaalministeeriumi poole
palvega toetada uude Ida-Tallinna Keskhaiglasse kiiritusravi integreerimist.
Dokumendid lisas.
Lugupidamisega
Marju Kase
Eesti Kliiniliste Onkoloogide Seltsi juhatuse esimees
[email protected]
Eesti Kliiniliste Onkoloogide Selts
L. Puusepa 8
51014 Tartu
Registri kood 80336381
E-post:
[email protected]
SEB: EE511010220237047224
Meie 05.09.18 nr 12.-09/01
Lugupeetud tervise- ja tööminister Riina Sikkut
Käesolevaga pöördub Eesti Kliiniliste Onkoloogide Selts (EKOS) Sotsiaalministeeriumi
poole palvega toetada uude Ida-Tallinna Keskhaiglasse kiiritusravi integreerimist.
Tsiteerides asekantsler Maris Jesse sõnu on Eesti suurimad terviseprobleemid need, mis
põhjustavad meile kõige suuremat haiguskoormust ehk enim haiguste ja suremuse tõttu
kaotatud eluaastaid. Teatavasti on kardiaalsed haigused ja vähk olnud maailmas, Euroopas
ning sealhulgas ka Eestis siiani juhtivateks surmapõhjusteks. Aastal 2016 avaldati USA
teadlaste poolt uurimus (Sidney et al. 2016), kus toodi esile, et kardioloogiline suremus on
viimasel kümnendil vähenenud 3 korda kiiremini kui vähisuremus kusjuures Šveitsis
vähisuremus juba ületab kardioloogilist suremust. Selline tendents viitab kohesele vajadusele
tagada Eestis nii optimaalne vähiravi kui ka efektiivseimate ravimetoodikate kättesaadavus.
2017.a. toimus Euroopa Parlamendis rahvusvaheline kiiritusravi ekspertide nõupidamine, kus
Eestit esindas Tartu Ülikooli Hematoloogia-onkoloogia kliiniku juhataja dots. Jana Jaal.
Selle tulemusena valminud lõppraportis on välja toodud vajadus kiiritusravi kättesaadavuse
parandamiseks koostöös valitsuste ning poliitikutega. Vaieldamatult on vähiravis haigete
elulemuse pikendamine esmane prioriteet. Teiseks ja mitte vähem oluliseks prioriteediks on
vähihaigete elukvaliteedi säilitamine ja parandamine. Nende ülesannete täitmiseks on
onkoloogias kasutusel efektiivsema ja radikaalsema ravimetoodikana kiiritusravi ning
piiratud ulatuses oluliselt vähemefektiivsetena kasvajavastased ravimid. Seejuures ravimeid
võidakse olla sunnitud kasutama, hoolimata kiiritusravi efektiivsemast mõjust kaebuste
leevendamisele, piiratud raviressursi tõttu (s.t. kiiritusravi aparaatide piiratud hulk ning
ravijärjekordade pikkus). Professor Josep M. Borras Barcelona Ülikoolist tõi 2017.a. Euroopa
Parlamendis peetud kõnes välja fakti, et 25% vähihaigetest jäävad ilma kiiritusravist, mida
nad hädasti vajavad. Hinnanguliselt vajavad kõikidest vähihaigetest mingil ravietapil
kiiritusravi ligikaudu 50-60% patsientidest. Oluline on siinjuures ka asjaolu, et vajadus
kiiritusravi järele pidevalt suureneb nii elanikkonna vananemisest tingitud suurema vähki
haigestumise kui ka kiiritusravi järjest laienevate näidustuste tõttu. Nii näiteks on see
ravimeetod kasutusel mitmete elundit säilitavate ja seeläbi parimat elukvaliteeti võimaldavate
raviprotokollide raames ning üha enam integreeritakse kiiritusravi ka metastaatilise haiguse
raviskeemidesse, sest lisaks medikamentoossele ravile pikendab kiiritusravi lisamine oluliselt
patsientide elulemust.
Hetkel on spetsialiseeritud vähiravi võimalik kolmes Eesti haiglas: SA Tartu Ülikooli
Kliinikumis, SA Põhja-Eesti Regionaalhaiglas ja AS Ida-Tallinna Keskhaiglas. Kõigis
kolmes haiglas tegelevad vähiraviga onkoloogid, kes oma erialaselt väljaõppelt vastavalt
Põhjamaades levinud õppemudelile on võimelised läbi viima nii kiiritus- kui keemiaravi.
Eelmainitud erialaõppe metoodika on valitud põhjusel, et just Põhjamaade vähihaigete
elulemus on maailmas kõrgeim ning selle üheks põhjuseks on onkoloogi individuaalne oskus
kombineerida vähiravis samaaegset või järjestikust kiiritus- ning keemiaravi ning ravida
võimalikke ravist tingitud kõrvaltoimeid.
Kui süsteemset vähiravi saavad patsiendid eelmainitud kolmes Eestis haiglas, siis kiiritusravi
osakonnad paiknevad ajaloolistelt väljakujunenult Tartu Ülikooli Kliinikumis ning Eesti
Onkoloogiakeskusest ületooduna Põhja-Eesti Regionaalhaiglas. Hetkel on Eestis 6
väliskiiritusravi aparaati (4,6 /1 milj elaniku kohta), millega paraku jääme endiselt allapoole
Euroopa mediaani. Ka siis, kui kahe regionaalhaigla plaanid täituksid ning Eesti saaks
täiendavalt juurde veel 4 kiiriitusravi masinat (neist 2 Põhja-Eesti Regionaalhaiglasse ning 2
Tartu Ülikooli Kliinikumi), siis jääksime me sellegi poolest ravi kättesaadavuse osas vaid
Põhjamaade 2013. aasta taseme juurde (Grau et al. 2014). Paraku peab tõdema, et sisuline
kvaliteetse ravi kättesaadavus kahjuks sellega oluliselt ei paraneks. Nimelt suureneb
elanikkonna vananemise ja suurema vähki haigestumise tõttu Euroopas juba aastaks 2025
hinnanguliselt kiiritusravi vajadus ligikaudu 16%. Samuti on viimasel kümnendil vähihaigete
väliskiiritusravis laialdaselt kasutusele võetud mitmeid uusi efektiivseid ravimeetodeid (nt.
täppiskiiritusravi, IMRT, IGRT, radiokemoteraapia). Kõik need eelmainitud metoodikad on
ühest küljest oluliselt tõhusamad ravitulemuse parandajad, olles oma radikaalsuselt
võrreldavad kirurgilise raviga (samas aga väheste ravikõrvaltoimetega ning rakendatavad
kehapiirkondades kus kirurgiline ravi ei oleks tehniliselt võimalik), kuid teisest küljest sellise
ülitäpsest kiiritusmahust tingituna ka väga töömahukad. See omakorda tingib patsientide
selekteerimise enne kiiritusravijärjekorda lisamist ning lõpptulemusena süvendab niigi
piiratud ligipääsu kiiritusravile. Kiiritusravi vähese kättesaadavuse tõttu eelistatakse
ravijärjekorra koostamisel patsiente, kelle kiiritusravi on tervistava eesmärgiga. Ülejäänud
juhtudel selekteeritakse patsiente vastavalt alternatiivsete ravivõimaluste olemasolule. Nii
näiteks moodustavad viimaste aastate Tartu Ülikooli Kliinikumi kiiritusravi patsientidest
~50% radikaalse radiokemoteraapia (samaaegne kiiritus- ja keemiaravi) patsiendid, mis viitab
otseselt kiiritusravi alakasutusele teistes patsiendigruppides (nt palliatiivset ravi vajavate
haigete grupis) piiratud ressursi tõttu. Ka on välja toodud (Grau et al. 2014), et lääneriikides
on iga kiiritusravi aparaadi kohta oluliselt vähem raviseansse kui vähemarenenud riikides,
kuna rohkem kasutatakse täpsemaid ning ressursimahukamaid ravimeetodeid
(täppiskiiritusravi, IMRT, IGRT, radiokemoteraapia). Teisisõnu on rikastes riikides rõhk
kvaliteedil ning vaesemates kvantiteedil. Paraku on kasvajahaigete ebavõrdus ravile
pääsemisel ja alaravi oluliseimad põhjused elulemuse paranemise näitajate puudumises, mida
rõhutatakse ka kogu Euroopat hõlmanud uuringu EUROCARE 5 kokkuvõttes.
Ida-Tallinna Keskhaiglal on käesolevaks hetkeks välja arendatud efektiivselt toimiv vähiravi
süsteem, kus haiglatevahelises onkoloogide koostöös on kiiritusravi vajavad patsiendid
suunatud vastavalt võimalusele eelistatult Põhja-Eesti Regionaalhaiglasse või Tartu Ülikooli
Kliinikumi. Kuna mõlemas Eesti kiiritusraviga tegelevas haiglas jätkuvad
raviressursiprobleemid, mis piiravad efektiivsemate ravimetoodikate laialdasemat
kasutuselevõtmist, siis ei ole lähemas tulevikus ette näha kvaliteetsema kiiritusravi
kättesaadavuse paranemist, rääkimata siis võimalustest kliiniliseks teadusarenduseks, mida
Tartu Ülikooli Kliinikumis püütakse alustada.
Väliskiiritusravi puudumine uues Ida-Tallinna Keskhaiglas loob olukorra, kus vähiravi
tegelik eesmärk - parim ravikvaliteet - jääb hoolimata uuest infrastruktuurist saavutamata.
Patsientide pendeldamine mitme haigla arstide vahel tekitab potentsiaalselt raviviivitusi
takistades parema ravitulemuse saavutamist, rääkimata patsientidele ebamugavuse
tekitamisest. Lisaks eeltoodule ei soodusta konkurentsi kunstlik mahasurumine jätkusuutlikku
arengut kvaliteedis vaid pigem soodustab monopoolse seisundi saavutanu mugandumist.
Richard Sullivan, Institute of Cancer Policy at King’s College direktor Londonist on öelnud,
et investeerimine ravimitesse tundub riigiametnikele alati seksikam. See loob illusiooni
võimalusse parandada kiirelt ning tõhusalt ravitulemusi. Kiiritusravi kättesaadavuse
parandamine on kindlasti üks mitteatraktiivsetest otsustest, sest nõuab suuremat ühekordset
investeeringut samas kui tulemused avalduvad alles aastate möödudes. Tegelikkuses
suurendab kiiritusravi investeeringute edasilükkamine Eestis edaspidi veelgi rohkem
vähihaigete selekteeritud ravile pääsu ning suurendab kulutusi alternatiivsetele
ravivõimalustele, seda eelkõige järjest kallinevas vähiravimite sektoris. Prof. Yolande
Lievens hinnangus Euroopa Parlamendile 2017.a toodi esile, et Euroopas moodustavad kulud
kiiritusravile vaid 5-10% vähiravi kogukuludest.
Kuna kiiritusravi, kui kirurgilise ravi kõrval teise kõige tähtsama tervistava ravimeetodi areng
Eestis on tervishoiupoliitiliselt äärmiselt oluline teema, siis selliste otsuste tegemisel oleks
mõistlik kaasata ka Tartu Ülikooli vastavaid eksperte, kelle vastutusalasse kuulub kogu
onkoloogiaga seonduv, s.h onkoloogide arvulise vajaduse hindamine, nende optimaalne
väljaõpe ning kes lisaks sellele suudavad näha erialalist tervikpilti, mis baseerub parimatele
tõenduspõhistele teadmistele ja kogemusele.
Eeltoodust lähtudes on EKOS hinnangul uues Ida-Tallinna Keskhaiglas Eesti vähiravi
kvaliteedi edasiseks tõstmiseks hädavajalik luua patsientidele võimalus saada lisaks
süsteemsele ning kirurgilisele ravile ka kiiritusravi.
Lugupidamisega
Marju Kase
Eesti Kliiniliste Onkoloogide Seltsi juhatuse esimees
[email protected]